The Cooper Companies, Inc. $COO Shares Sold by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG trimmed its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 72.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,225 shares of the medical device company’s stock after selling 29,978 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Cooper Companies were worth $770,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wealth Alliance LLC grew its stake in shares of Cooper Companies by 4.2% during the second quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock worth $301,000 after purchasing an additional 171 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its stake in Cooper Companies by 1.3% in the third quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock valued at $961,000 after buying an additional 175 shares in the last quarter. Pacer Advisors Inc. raised its stake in Cooper Companies by 0.8% in the third quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock valued at $1,582,000 after buying an additional 182 shares in the last quarter. Citizens Financial Group Inc. RI lifted its holdings in Cooper Companies by 2.7% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock worth $492,000 after buying an additional 192 shares during the last quarter. Finally, Close Asset Management Ltd boosted its position in shares of Cooper Companies by 7.2% during the 3rd quarter. Close Asset Management Ltd now owns 3,319 shares of the medical device company’s stock worth $227,000 after acquiring an additional 224 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley boosted their target price on Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a research note on Monday, December 8th. Needham & Company LLC raised their price objective on shares of Cooper Companies from $99.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the stock a “buy” rating in a research report on Friday, December 5th. Piper Sandler restated an “overweight” rating and issued a $94.00 target price (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Finally, Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

COO stock opened at $73.75 on Thursday. The company has a current ratio of 1.34, a quick ratio of 0.79 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $14.39 billion, a P/E ratio of 36.51, a PEG ratio of 1.92 and a beta of 1.02. The business has a 50 day simple moving average of $81.66 and a 200-day simple moving average of $76.00. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Insiders Place Their Bets

In related news, insider Holly R. Sheffield purchased 1,230 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were purchased at an average price of $80.75 per share, for a total transaction of $99,322.50. Following the transaction, the insider directly owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. The trade was a 3.25% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction on Wednesday, December 17th. The shares were bought at an average cost of $82.50 per share, with a total value of $165,000.00. Following the completion of the purchase, the director owned 7,777 shares in the company, valued at $641,602.50. The trade was a 34.62% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 16,014 shares of company stock valued at $1,304,416. 2.08% of the stock is owned by insiders.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.